Menu
support our cause

REFERENCE LIST

  1. Lowenthal RM, Eaton K (1996). Toxicity of chemotherapy. Hematol Oncol Clin North Am. 10(4):967-90.
  2. Woodcock J, Griffin JP, Behrman RE (2011). Development of novel combination therapies. N Engl J Med. 364:985-987.
  3. Amjad MT, Chidharla A, Kasi A (2022). Cancer Chemotherapy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. PMID: 33232037.
  4. Cridge BJ, Larsen L, Rosengren RJ (2013). Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers. Oncol. Disc. [Online] Available from: http://www.hoajonline.com/journals (Accessed on 07/08/2022).
  5. Ranjan A, Ramachandran S, Gupta N, Kaushik I, Wright S, et al (2019). Role of phytochemicals in cancer prevention. Int J Mol Sci. 20(20):4981.
  6. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, et al (2006). Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol. 4:1035–1038.
  7. Lai HW, Chien SY, Kuo SJ, Tseng LM, Lin HY, et al (2012). The potential utility of curcumin in the treatment of Her-2-overexpressed breast cancer: an in vitro and in vivo comparison study with herceptin. Evid Based Complement Alternat Med. 2012:Article ID 486568.
  8. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al (2001). Phase I clinical trial of curcumin a chemopreventive agent in patients with high-risk or pre-malignant lesions. Anticancer Res. 21:2895–2900.
  9. Glasauer A, Chandel NS (2014). Targeting antioxidants for cancer therapy. Biochem Pharmacol. 92:90–101.
  10. Bishayee A (2009). Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res. 2:409–418.
  11. Yu M, Xue J, Li Y, Zhang W, Ma D, et al (2013). Resveratrol protects against arsenic trioxide-induced nephrotoxicity by facilitating arsenic metabolism and decreasing oxidative stress. Arch Toxicol. 87:1025–1035.
  12. Zhu Y, Mao Y, Chen H, Lin Y, Hu Z, et al (2013). Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells. Cancer Cell Int. 13:54.
  13. Yang J, Pi C, Wang G (2018). Inhibition of PI3K/Akt/MTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed Pharmacother. 103:699–707.
  14. Erker L, Schubert R, Yakushiji H, Barlow C, Larson D, et al (2005). Cancer chemoprevention by the antioxidant tempol acts partially via the p53 tumor suppressor. Hum Mol Genet. 14:1699–1708.
  15. Adjakly M, Ngollo M, Boiteux JP, Bignon YJ, Guy L, Bernard-Gallon D (2013). Genistein and Daidzein: different molecular effects on prostate cancer. Anticancer Res. 33:39–44.
  16. George BP, Chandran R, Abrahamse H (2021). Role of phytochemicals in cancer chemoprevention: Insights. Antioxidants (Basel). 10(9):1455.
IMBIOSCIENCES RESEARCH INSTITUTE
IMBRI is a registered non-profit organization (Reg no: 277-047 NPO), with tax-exempt status (PBO ref no : 930078778) - All Rights Reserved
A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.